Icodextrin enhances survival in an intraperitoneal ovarian cancer murine model utilizing gene therapy

Gynecologic Oncology

Volumn 103, Issue 3, 2006, Pages 985-989

  Rocconi, Rodney P ^a   Numnum, Michael T ^a   Zhu, Zeng B ^b   Lu, Baogen ^b   Wang, Minghui ^b   Rivera, Angel A ^b   Stoff Khalili, Mariam ^b   Alvarez, Ronald D ^a   Curiel, David T ^b   Makhija, Sharmila ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

Gene therapy; Icodextrin; Intraperitoneal; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; DELTA24 ARGINYLGLYCYLASPARTIC ACID; ICODEXTRIN; PHOSPHATE BUFFERED SALINE;

ADENOVIRUS VECTOR; ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCULATION; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER MODEL; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; DIALYSATE; DRUG EFFECT; DRUG INSTILLATION; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KAPLAN MEIER METHOD; LOG RANK TEST; MONOTHERAPY; MOUSE; NONHUMAN; OVARY CANCER; PERITONEAL DIALYSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS INFECTIVITY; VIRUS PARTICLE; VIRUS REPLICATION;

ANIMALS; DIALYSIS SOLUTIONS; DISEASE MODELS, ANIMAL; FEMALE; GENE THERAPY; GLUCANS; GLUCOSE; INFUSIONS, PARENTERAL; MICE; OVARIAN NEOPLASMS;

EID: 33751535219     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.06.005     Document Type: Article

References (17)

1. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., et al. Cancer statistics, 2005. CA Cancer J. Clin. 55 (2005) 10-30
2. Dedrick R.L., Myers C.E., Bungay P.M., and DeVita Jr. V.T. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 62 (1978) 1-11
3. Markman M. Intraperitoneal chemotherapy. Semin. Oncol. 18 (1991) 248-254
4. Dedrick R.L., and Flessner M.F. Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J. Natl. Cancer Inst. 89 (1997) 480-487
5. Alberts D.S., Liu P.Y., Hannigan E.V., O'Toole R., Williams S.D., Young J.A., et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N. Engl. J. Med. 335 (1996) 1950-1955
6. Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354 (2006) 34-43
7. Markman M., Bundy B.N., Alberts D.S., Fowler J.M., Clark-Pearson D.L., Carson L.F., et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J. Clin. Oncol. 19 (2001) 1001-1007
8. Alvarez R.D., Gomez-Navarro J., Wang M., Barnes M.N., Strong T.V., Arani R.B., et al. Adenoviral-mediated suicide gene therapy for ovarian cancer. Mol. Ther. 2 (2000) 524-530
9. Buller R.E., Runnebaum I.B., Karlan B.Y., Horowitz J.A., Shahin M., Buekers T., et al. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther. 9 (2002) 553-566
10. Coukos G, Rubin SC: Gene therapy for ovarian cancer. Oncology (Williston Park) 2001; 15: 1197-1204, 1207; discussion 1207-1198.
11. Hortobagyi G.N., Ueno N.T., Xia W., Zhang S., Wolf J.K., Putnam J.B., et al. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J. Clin. Oncol. 19 (2001) 3422-3433
12. Tait D.L., Obermiller P.S., Hatmaker A.R., Redlin-Frazier S., and Holt J.T. Ovarian cancer BRCA1 gene therapy: phase I and II trial differences in immune response and vector stability. Clin. Cancer Res. 5 (1999) 1708-1714
13. Hosie K., Gilbert J.A., Kerr D., Brown C.B., and Peers E.M. Fluid dynamics in man of an intraperitoneal drug delivery solution: 4% icodextrin. Drug Deliv. 8 (2001) 9-12
14. Engler H., Machemer T.R., Schluep T., Wen S.F., Quijano E., Wills K.N., et al. Development of a formulation that enhances gene expression and efficacy following intraperitoneal administration in rabbits and mice. Mol. Ther. 7 (2003) 558-564
15. Suzuki K., Fueyo J., Krasnykh V., Reynolds P.N., Curiel D.T., and Alemany R. A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin. Cancer Res. 7 (2001) 120-126
16. Bauerschmitz G.J., Lam J.T., Kanerva A., Suzuki K., Nettelbeck D.M., Dmitriev I., et al. Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res. 62 (2002) 1266-1270
17. van den Tol P., ten Raa S., van Grevenstein H., Marquet R., van Eijck C., and Jeekel H. Icodextrin reduces postoperative adhesion formation in rats without affecting peritoneal metastasis. Surgery 137 (2005) 348-354